Eric Murphy, Ph.D., has been appointed global scientific director for translational oncology at Crown Bioscience.

Most recently, Dr. Murphy designed and implemented a screening operation for a biotechnology company focused on regenerative medicine that led to phenotypic screening and compound profiling to support both discovery and translational research programs. The unit also performed translational research for clinical programs for cancer, osteoarthritis and alopecia.

Working for a large global pharmaceutical company, he employed numerous in vivo efficacy studies to identify new targets and in vitro high throughput phenotypic screens to identify new chemical starting points while building an extensive network of academic collaborations to perform translational and drug discovery research.

“For more than 20 years, Dr. Murphy has focused on translational and drug discovery research for some of the most respected academic and biopharmaceutical organizations in the world,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience. “Working with our innovative research and development teams to leverage our scientific platforms, he will assist clients with early preclinical studies and support clinical development strategies to translate new cancer therapeutics.”